Clinical Chemistry Link to Randox Laboratories Web Site
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 50: 1489-1491, 2004; 10.1373/clinchem.2004.034314
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Morrow, D. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Morrow, D. A.
Related Collections
Right arrow Evidence Based Laboratory Medicine and Test Utilization
Right arrow Proteomics and Protein Markers
Right arrow Lipids, Lipoproteins, and Cardiovascular Risk Factors
Right arrow Heart Health and the Clinical Laboratory
(Clinical Chemistry. 2004;50:1489-1491.)
© 2004 American Association for Clinical Chemistry, Inc.

Editorials

Preprocedural C-Reactive Protein for Risk Prediction Before Percutaneous Coronary Intervention (PCI): A US Perspective

David A. Morrow

1 TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham & Women’s Hospital, Boston, MA

Address for correspondence: Cardiovascular Division, Brigham and Women’s Hospital, 75 Francis St., Boston, MA 02115. Fax 617-734-7139; e-mail dmorrow@partners.org.

The first 20% of the full text of this article appears below.

Percutaneous coronary intervention (PCI), which includes percutaneous transluminal coronary angioplasty (PTCA) and coronary stenting, has continued expanding its role in the management of coronary atherosclerosis. Major advances in the technical aspects of PCI (especially coronary stents) have had a favorable impact on both early and long-term outcomes(1). Although bare-metal stents have dramatically reduced the incidence of angiographic (>50% stenosis at site of previous PCI) and clinical restenosis (repeat coronary intervention prompted by evidence of recurrent ischemia) compared with balloon angioplasty, restenosis within the stent occurs in 15–30% of cases and has remained a limitation to the long-term success of PCI. The pathogenesis of restenosis is multifactorial and includes smooth muscle cell proliferation and migration, extracellular matrix production, organization of thrombus, elastic recoil, and negative remodeling. Stent implantation, in particular, precipitates arterial intimal cellular proliferation and extracellular matrix synthesis mediated largely by inflammatory processes(2). Because of these considerable contributions of inflammation, preprocedural measurement of the inflammatory marker C-reactive protein (CRP) has been proposed as a method to identify patients at higher risk of restenosis. The report from Rittersma et al.(3) in this issue, however, adds to the aggregate base of evidence that should shift the clinician’s focus from recurrence at a focal site of recent intervention to prevention of events related to vulnerable atheroma elsewhere in the coronary bed.


preprocedural crp and restenosis

Data regarding the relationship between . . . [Full Text of this Article]


preprocedural crp and clinical outcomes


clinical implications


conclusions






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2004 by the American Association for Clinical Chemistry.